β2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1176-1181

  Giorgetti, Sofia ^a   Raimondi, Sara ^a,b   Cassinelli, Silvia ^a,b   Bucciantini, Monica ^c,d   Stefani, Massimo ^c,d   Gregorini, Gina ^e   Albonico, Giulia ^b   Moratti, Remigio ^b   Montagna, Giovanni ^f   Stoppini, Monica ^a,g   Bellotti, Vittorio ^a,b,h  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Department of Biochemistry ^*

^d UNIVERSITY OF FLORENCE   (Italy)

^e Ospedale Civile di Brescia   (Italy)

^f IRCCS   (Italy)

^g NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^h Dipartimento di Biochimica   (Italy)

Author keywords

Blood brain barrier; Cerebrospinal fluid; Cytotoxicity; Dialysis related amyloidosis; Oligomers

Indexed keywords

BETA 2 MICROGLOBULIN;

ARTICLE; ASSAY; BLOOD BRAIN BARRIER; BRAIN LEVEL; BRAIN PROTECTION; BRAIN TOXICITY; CELL CULTURE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOTOXICITY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IMMUNONEPHELOMETRY; NEPHELOMETRY; NEUROBLASTOMA CELL; NEUROTOXICITY; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WESTERN BLOTTING; BRAIN; NEUROBLASTOMA; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; TUMOR CELL LINE;

BETA 2-MICROGLOBULIN; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TUMOR; COGNITION DISORDERS; HUMANS; NEUROBLASTOMA; RENAL DIALYSIS;

EID: 65349160016     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn623     Document Type: Article

References (21)

1. Gejyo F, Homma N, Suzuki Y et al. Serum levels of beta2- microglobulin as a newformof amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 1986; 314: 585-586
2. Relini A, Canale C, De Stefano S et al. Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem 2006; 281: 16521-16529
3. Relini A, De Stefano S, Torrassa S et al. Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem 2008; 283: 4912-4920
4. Stoppini M, Mangione P, Monti M et al. Proteomics of beta2- microglobulin amyloid fibrils. Biochim Biophys Acta 2005; 1753: 23-33
5. Giorgetti S, Stoppini M, Tennent GA et al. Lysine 58-cleaved beta2- microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Sci 2007; 16: 343-349
6. Corlin DB, Sen JW, Ladefoged S et al. Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. Clin Chem 2005; 51: 1177-1184
7. Yoshinaga T, Takei Y, Katayanagi K et al. Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30Met transthyretin gene. Amyloid 2004; 11: 56- 60
8. Brett M, Persey MR, Reilly MM et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999; 122: 183-190
9. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 2008; 15: 123-132
10. Wu CH, Rastegar M, Gordon J et al. Beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein. Oncogene 2001; 20: 7006-7020
11. Menaa C, Esser E, Sprague SM. Beta(2)-microglobulin stimulates osteoclast formation. Kidney Int 2008; 73: 1275-1281
12. Esposito G, Michelutti R, Verdone G et al. Removal of the N-terminal hexapeptide from human 2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci 2000; 9: 831-845
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
14. Stoppini M, Bellotti V, Mangione P et al. Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils. Eur J Biochem1997; 249: 21-26
15. Cecchi C, Pensalfini A, Baglioni S et al. Differing molecular mechanisms appear to underlie early toxicity of prefibrillar HypFN aggregates to different cell types. FEBS J 2006; 273: 2206- 2222
16. Cecchi C, Pensalfini A, Stefani M et al. Replicating neuroblastoma cells in different cell cycle phases display different vulnerability to amyloid toxicity. J MolMed 2008; 86: 197-209
17. Piazza R, Pierno M, Iacopini S et al. Micro-heterogeneity and aggregation in beta2-microglobulin solutions: effects of temperature, pH, and conformational variant addition. Eur Biophys J 2006; 35: 439- 445
18. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006; 13: 266-272
19. Jeffery GM, Frampton CM, Legge HM et al. Cerebrospinal fluid β2-microglobulin levels in meningeal involvement by malignancy. Pathology 1990; 22: 20-23
20. Gordon J, Wu CH, Rastegar M et al. Beta2-microglobulin induces caspase-dependent apoptosis in the CCRF-HSB-2 human leukemia cell line independently of the caspase-3, -8 and -9 pathways but through increased reactive oxygen species. Int J Cancer 2003; 103: 316-327
21. Caudie C, Bancel J, Dupont M et al. CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin. Ann Biol Clin 2005; 63: 631-637